People with autosomal-dominant mutations in APP or presenilin genes develop early onset Alzheimer’s disease. Could a healthy lifestyle mitigate this genetic misfortune? A new study indicates that it may. A cross-sectional study of participants in the Dominantly Inherited Alzheimer Disease Network (DIAN) suggests that higher levels of physical activity associate with better cognitive performance, and less amyloid in the brain. The results are consistent with findings in sporadic AD, and suggest that exercise also benefits people with genetically driven disease. The study, led by Stephan Müller and Christoph Laske of the University of Tübingen in Germany, appeared September 25 in Alzheimer’s & Dementia.
- Exercise staves off dementia in the elderly, but what about people with early onset AD?
- In familial cases, physical activity correlated with better cognition and less disease pathology.
- The study does not establish cause and effect.
The study is the first report of an association between self-reported physical activity and cognitive status in patients with familial Alzheimer’s disease, wrote Antonio Muscari, University of Bologna, Italy, in an email to Alzforum. He stressed that the study shows association, not necessarily causation. “Still, this paper favors the idea that physical activity may be considered an important therapeutic tool for patients at risk of cognitive decline, including those with autosomal-dominant AD,” Muscari said.
The findings may have implications for late-onset, idiopathic AD as well. Studies in familial AD may help us understand what happens in sporadic disease, said Belinda Brown, Murdoch University, Perth, Australia. “By utilizing data from the DIAN families we can evaluate the role physical activity plays in reducing Alzheimer’s disease risk and progression in people who are destined to accumulate amyloid at an early age; thus they provide an excellent model for this type of research,” she wrote to Alzforum.
It has long been known that regular exercise staves off age-related cognitive decline, but the effects of physical activity on amyloid load have been less clear (Mar 2016 news). A small study indicated that exercise slowed amyloid accumulation in presymptomatic AD mutation carriers who already had some amyloid in the brain (Brown et al., 2017). To expand on that study, Müller and colleagues drew on data tallying physical activity, cognitive performance, and biomarkers of amyloid load at baseline among 224 DIAN participants who carry familial AD mutations and 148 healthy, age-matched noncarriers. The carriers averaged 38 years old and spanned the course of the disease, including both asymptomatic and symptomatic volunteers. Participants reported the amount of time they spent over the preceding year doing any of 10 different activities, including walking, cycling, or tennis. A family member or friend corroborated the self-reports. On average, both mutation carriers and noncarriers spent an impressive five hours per week exercising. Among carriers, levels of physical activity were lower in those who were closer to their expected age of disease onset.
Among the mutation carriers, the researchers identified a complex dose response whereby up to about 6.5 hours per week, more exercise associated with better scores on the Mini Mental State Exam (MMSE) and on the Clinical Dementia Rating scale Sum of Boxes (CDR-SOB). At this level of exercise, MMSE scores approached those of age-matched noncarriers. Above about eight hours of exercise per week, MMSE declined. The CDR-SOB followed a similar pattern. Exercise did not relate to cognitive scores in healthy noncarriers.
To delve deeper, Müller divided the mutation carriers into high-activity and low-activity groups, using 2.5 hours per week as the cutoff value. This is the amount of exercise recommended by the World Health Organization, and was achieved by 70 percent of the mutation carriers. On average, the high-activity group was four years younger and hence further from their predicted disease onset than the low-activity group. Perhaps not surprisingly, the high-activity group scored significantly better on the MMSE, CDR global, and CDR-SOB than the low-activity group. They also had higher CSF biomarker Aβ1-42, and lower CSF total tau and phospho-tau, all indicative of less AD pathology. Global PiB uptake, a measure of brain amyloid, was slightly lower in the more active group, but the difference was not statistically significant.
When Müller used linear regression to model changes over time, correcting for age and time to disease onset, exercise still appeared to have benefits. Those exercising more had better cognitive function relative to their estimated year to onset (EYO) of dementia than did those who exercised less. At the time when symptoms were predicted to start, the more active group scored 3.4 points better on the MMSE and they reached the CSD-SOB cutoff for mild dementia 15 years later than the less-active group. Along with an apparent slowing of cognitive decline, modeled trajectories of CSF total tau and the total tau/Aβ1-42 ratio were attenuated in the high activity group, indicative of less tau and Aβ pathology.
Laske was surprised exercise had such a strong effect. “In familial AD, we suppose that the genes are the main drivers, and we didn’t expect that a lifestyle intervention, such as physical activity, could have such strong effects,” he told Alzforum.
Nonetheless, the authors and several commentators cautioned that the data do not prove cause and effect. “With cross-sectional data, we cannot clearly say if higher physical activity is the reason for better cognition, or if better cognition is associated with higher activity,” Laske said. Definitively nailing the effect of exercise will take true longitudinal data, said Laske. In the DIAN study, many participants have by now accumulated five to six years of follow-up data, and Laske is in the process of analyzing those trajectories. Other ADAD cohorts are also collecting information on exercise, with plans to examine the impact of physical activity, wrote Jessica Langbaum of Banner Health Institute, Phoenix, Arizona, in an email to Alzforum (see complete comment below).
“The paper is interesting and is consistent with a lot of other research that indicates a protective association between exercise and the risk of AD, dementia, and cognitive performance,” wrote Eric Larson, Kaiser Permanente Washington Health Research Institute, Seattle, in an email to Alzforum. Larson noted the participants are not typical of the population as a whole, since less than 50 percent of U.S. adults get the recommended 150 minutes of physical activity per week.
Mark Mattson, National Institute of Aging in Bethesda, Maryland thinks the results call for an intervention trial of exercise in familial AD. “It would be good to see if you could actually delay the onset in people who know they would get AD,” he said. He’d also like to see analysis of potential covariates: Perhaps people who exercise more have lower body mass and better glucose control, both of which reduce AD risk, he said.—Pat McCaffrey
- Brown BM, Sohrabi HR, Taddei K, Gardener SL, Rainey-Smith SR, Peiffer JJ, Xiong C, Fagan AM, Benzinger T, Buckles V, Erickson KI, Clarnette R, Shah T, Masters CL, Weiner M, Cairns N, Rossor M, Graff-Radford NR, Salloway S, Vöglein J, Laske C, Noble J, Schofield PR, Bateman RJ, Morris JC, Martins RN, Dominantly Inherited Alzheimer Network. Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. Alzheimers Dement. 2017 Nov;13(11):1197-1206. Epub 2017 May 11 PubMed.
No Available Further Reading
- Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C . Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, Sept. 25, 2018, In Press